Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Accumulated Expenses (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Accumulated Expenses for 13 consecutive years, with $45.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses fell 2.99% year-over-year to $45.5 million, compared with a TTM value of $45.5 million through Dec 2025, down 2.99%, and an annual FY2025 reading of $45.5 million, down 2.99% over the prior year.
  • Accumulated Expenses was $45.5 million for Q4 2025 at Agios Pharmaceuticals, up from $37.2 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $46.9 million in Q4 2024 and bottomed at $19.7 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $31.8 million, with a median of $30.4 million recorded in 2022.
  • The sharpest move saw Accumulated Expenses crashed 41.21% in 2021, then surged 42.23% in 2023.
  • Year by year, Accumulated Expenses stood at $32.0 million in 2021, then dropped by 5.06% to $30.4 million in 2022, then soared by 42.23% to $43.2 million in 2023, then rose by 8.56% to $46.9 million in 2024, then fell by 2.99% to $45.5 million in 2025.
  • Business Quant data shows Accumulated Expenses for AGIO at $45.5 million in Q4 2025, $37.2 million in Q3 2025, and $35.3 million in Q2 2025.